Dernières nouvelles pour IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

IDEXX Laboratories Inc

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

GILD

IDXX

PRGO

REGN

TEVA

VTRS

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

IDEXX Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NYSE">IDXX</a>) short percent of float has fallen 21.91% since its last report. The company recently reported that it has 1.62 million shares sold short, which is 2.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>IDEXX Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733772611_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for IDEXX Laboratories has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing IDEXX Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, IDEXX Laboratories's peer group average for short interest as a percentage of float is 3.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(IDXX) - Analyzing IDEXX Laboratories's Short Interest

Buybacks

IDEXX Laboratories Board Authorizes Increase In Its Ongoing Share Repurchase Program, Authorizing Repurchase Of Up To 5M Additional Shares

5 analysts have shared their evaluations of IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $498.2, a high estimate of $575.00, and a low estimate of $435.00. A 10.64% drop is evident in the current average compared to the previous average price target of $557.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733155251_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of IDEXX Laboratories by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Clark</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$500.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$435.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$481.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$575.00</td>
<td>$630.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$500.00</td>
<td>$510.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IDEXX Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IDEXX Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into IDEXX Laboratories's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IDXX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IDEXX Laboratories analyst ratings.</a>
<h2>About IDEXX Laboratories</h2>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>Key Indicators: IDEXX Laboratories's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining IDEXX Laboratories's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.56% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: IDEXX Laboratories's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 23.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): IDEXX Laboratories's ROE excels beyond industry benchmarks, reaching 14.56%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): IDEXX Laboratories's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.88%, the company showcases efficient use of assets and strong financial health.
Debt Management: IDEXX Laboratories's debt-to-equity ratio surpasses industry norms, standing at 0.62. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On IDEXX Laboratories Through 5 Analysts

Leerink Partners analyst Daniel Clark initiates coverage on IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Outperform rating and announces Price Target of $500.

Price Target

Initiation

Leerink Partners Initiates Coverage On IDEXX Laboratories with Outperform Rating, Announces Price Target of $500

Management

IDEXX Names Andrew Emerson To Serve As Next CFO, Effective March 1, 2025; Brian McKeon To Retire In June 2025

Throughout the last three months, 5 analysts have evaluated IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $502.2, a high estimate of $575.00, and a low estimate of $435.00. This current average has decreased by 11.27% from the previous average price target of $566.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1730750450_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of IDEXX Laboratories among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$435.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$481.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$575.00</td>
<td>$630.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$500.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$520.00</td>
<td>$600.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IDEXX Laboratories. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of IDEXX Laboratories compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for IDEXX Laboratories's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of IDEXX Laboratories's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IDXX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IDEXX Laboratories analyst ratings.</a>
<h2>Delving into IDEXX Laboratories's Background</h2>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>Unraveling the Financial Story of IDEXX Laboratories</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: IDEXX Laboratories's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.56%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: IDEXX Laboratories's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 23.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): IDEXX Laboratories's ROE stands out, surpassing industry averages. With an impressive ROE of 14.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): IDEXX Laboratories's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.88% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.62.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 5 Analyst Evaluations For IDEXX Laboratories

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 10 years by 7.62% on an annualized basis producing an average annual return of 18.45%. Currently, IDEXX Laboratories has a market capitalization of $34.06 billion. 
Buying $1000 In IDXX: If an investor had bought $1000 of IDXX stock 10 years ago, it would be worth $5,623.32 today based on a price of $413.82 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730746817_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today

Piper Sandler analyst David Westenberg reiterates IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Neutral and lowers the price target from $520 to $435.

Reiteration

Piper Sandler Reiterates Neutral on IDEXX Laboratories, Lowers Price Target to $435

Barclays analyst Balaji Prasad maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Overweight and lowers the price target from $570 to $481.

Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $481

Idexx Laboratories&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)&nbsp;reported third-quarter adjusted EPS of $2.79, up 12% year-over-year,&nbsp;<a href="https://www.benzinga.com/pressreleases/24/08/b40182394/idexx-laboratories-announces-second-quarter-results" target="_blank" rel="noreferrer noopener">beating the consensus of $2.68</a>.
The company reported sales of $975.54 million, an increase of 7% as reported and 6% organically, missing the consensus of <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $979.18 million</a>.
Organic revenue growth is supported by benefits from IDEXX execution drivers, including continued solid new business gains and double-digit year-over-year global premium installed base growth.
The revenue growth&nbsp;was driven by Companion Animal growth of 7%, as reported, and 6% organic, and Water revenue growth of 13% as reported and organic.
&#8220;IDEXX teams continued their strong execution in the third quarter as demonstrated by solid net customer gains, continued growth in our premium IDEXX VetLab instrument installed base, and nearly 700 pre-orders of IDEXX inVue Dx Cellular Analyzer, which will begin shipping later in the fourth quarter,&#8221; said Jay Mazelsky, president and CEO. &#8220;Customers especially value IDEXX technology solutions like inVue Dx that provide meaningful clinical insights while giving time back to busy practice staff.&#8221;
Guidance: IDEXX Laboratories expects full-year revenue of $3.865 billion-$3.89 billion <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40196785/animal-health-firm-idexxs-robust-business-model-bolsters-position-despite-slower-gr" target="_blank" rel="noreferrer noopener">versus prior guidance</a> of $3.885 billion-$3.945 billion and consensus of $3.92 billion.
The company forecasts full-year adjusted EPS of $10.37-$10.53 versus prior guidance of $10.31-$10.59 and a consensus of $10.56.
William Blair notes that this quarter's slower growth stemmed from a continued decline in veterinary office visits, a trend that has been ongoing for several quarters, even as year-over-year growth comparisons become easier. 
Investors are now focusing on the industry's growth outlook for 2025, particularly wondering if and when some stability in end-market visits might occur.
Despite these ongoing volume declines posing a short-term growth challenge, the analyst remains optimistic about long-term growth drivers, especially the lasting impact of increased pet ownership from the COVID-19 pandemic-era puppy boom.
Price Action: IDXX stock is down 9.44% at $408.51 at publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41656437/cignas-q3-profit-beats-street-on-strong-demand-for-pharmacy-benefit-managements-specialty-drugs-new" target="_blank" rel="noreferrer noopener">Cigna&#8217;s Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management&#8217;s Specialty Drugs, New Clients</a></li>
</ul>
Photo: SeventyFour via Shutterstock

Earnings

Guidance

Movers

Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth

WIIM

IDEXX Laboratories shares are trading lower after the company reported a Q3 revenue miss and issued guidance below estimates.

<ul>
<li>Narrows 2024 EPS outlook to $10.37 - $10.53, maintaining consistent EPS midpoint compared to prior guidance, supported by consistent outlook for solid operating margin performance and benefits from lower projected interest expense and effective tax rate.</li>
</ul>

IDEXX Laboratories Expects 2024 Adjusted EPS Of $10.37-$10.53 Versus Prior Guidance Of $10.31-$10.59 And Consensus Of $10.56

<ul>
<li>Adjusts 2024 revenue guidance to $3,865 million - $3,890 million, a reduction of $38 million or ~1% at midpoint, incorporating expectations for near-term negative impacts on growth related to macro and sector conditions constraining pet owner visits and demand at U.S. veterinary clinics.</li>
<li>Updates 2024 revenue growth guidance to 5.5% - 6.2% as reported and 5.3% - 6.0% organic, driven by projected CAG Diagnostics recurring revenue growth of 5.6% - 6.2% as reported and 5.8% - 6.4% organic.</li>
</ul>

IDEXX Laboratories Expects 2024 Revenue Of $3.865B-$3.89B Versus Prior Guidance Of $3.885B-$3.945B And Consensus Of $3.92B

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) reported quarterly earnings of $2.79 per share which beat the analyst consensus estimate of $2.68 by 4.1 percent. This is a 12.05 percent increase over earnings of $2.49 per share from the same period last year. The company reported quarterly sales of $975.54 million which missed the analyst consensus estimate of $979.18 million by 0.37 percent. This is a 6.56 percent increase over sales of $915.53 million the same period last year.

IDEXX Laboratories Q3 2024 Adj EPS $2.79 Beats $2.68 Estimate, Sales $975.54M Miss $979.18M Estimate

Ratings for IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated IDEXX Laboratories and provided 12-month price targets. The average target is $543.75, accompanied by a high estimate of $580.00 and a low estimate of $500.00. Observing a downward trend, the current average is 6.25% lower than the prior average price target of $580.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728658809_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive IDEXX Laboratories is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$575.00</td>
<td>$630.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$500.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$520.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$580.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to IDEXX Laboratories. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of IDEXX Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of IDEXX Laboratories's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into IDEXX Laboratories's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IDXX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IDEXX Laboratories analyst ratings.</a>
<h2>Delving into IDEXX Laboratories's Background</h2>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>Breaking Down IDEXX Laboratories's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: IDEXX Laboratories's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.35%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: IDEXX Laboratories's net margin excels beyond industry benchmarks, reaching 20.26%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): IDEXX Laboratories's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 12.91%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): IDEXX Laboratories's ROA excels beyond industry benchmarks, reaching 6.01%. This signifies efficient management of assets and strong financial health.
Debt Management: IDEXX Laboratories's debt-to-equity ratio is below the industry average at 0.68, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About IDEXX Laboratories Stock

JP Morgan analyst Chris Schott maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Overweight and lowers the price target from $630 to $575.

JP Morgan Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $575

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 20 years by 3.56% on an annualized basis producing an average annual return of 12.15%. Currently, IDEXX Laboratories has a market capitalization of $38.56 billion. 
Buying $100 In IDXX: If an investor had bought $100 of IDXX stock 20 years ago, it would be worth $979.31 today based on a price of $468.45 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728581432_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today

Stifel analyst Jonathan Block maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Hold and lowers the price target from $510 to $500.

Stifel Maintains Hold on IDEXX Laboratories, Lowers Price Target to $500

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 10 years by 12.36% on an annualized basis producing an average annual return of 23.75%. Currently, IDEXX Laboratories has a market capitalization of $42.12 billion. 
Buying $100 In IDXX: If an investor had bought $100 of IDXX stock 10 years ago, it would be worth $846.20 today based on a price of $511.78 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727470822_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 10 Years

Invesco American Franchise Fund Q3 2024 Commentary

Zoetis: Healing Paws, Growing Profits

Leerink analyst Daniel Clark initiated coverage of Idexx Laboratories (IDXX) with an Outperform rating and $500 price target The firm notes Idexx L...

Idexx Laboratories initiated with an Outperform at Leerink

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Tesla upgraded, Autodesk initiated: Wall Street's top analyst calls

Tracking Terry Smith's Fundsmith 13F Portfolio - Q3 2024 Update

IDEXX Laboratories reloads buyback firepower

IDEXX Laboratories (IDXX) announced that the Company's Board of Directors authorized an increase in its ongoing share repurchase program, authorizi...

Idexx  Laboratories announces 5M share increase in share repurchase pact

An announcement from Idexx Laboratories ( ($IDXX) ) is now available. IDEXX Laboratories has approved a Nonqualified Deferred Compensation Plan all...

Idexx Laboratories Approves Nonqualified Deferred Compensation Plan

In a report released today, Erin Wright from Morgan Stanley maintained a Buy rating on Idexx Laboratories (IDXX – Research Report), with a price ta...

Morgan Stanley Remains a Buy on Idexx Laboratories (IDXX)

Tracking Ron Baron's BAMCO Portfolio - Q3 2024 Update

AAPL

ACGL

ACGLN

ACGLO

ADSK

AKAM

AMZN

ANSS

ASML

AVGO

BKLN

CACI

CQQQ

CSGP

DASH

DXCM

EXPO

FLUT

FSLY

FTNT

GKOS

GLPI

GOOG

GOOGL

GWRE

IRDM

KBWB

KBWD

KBWY

KNSL

LDOS

LRLCF

MORN

MSCI

MSFT

NONOF

NVDA

OKTA

ORLY

OTIS

PCEF

PCOR

PDBC

PDYPY

PNQI

PRFZ

QQQJ

QQQM

RSPT

SAIC

SCHW

SOXQ

SPGI

SPGP

SPHB

SPHD

SPHQ

SPLV

SPMO

TECH

TOST

TSLA

UPST

VRSK

VRSN

XMMO

Press Releases

IDEXX Laboratories to Release 2024 Second Quarter Financial Results

IDEXX Releases 2023 Corporate Responsibility Report, Highlighting Progress Against Its Goals

IDEXX Laboratories Announces Time Change for 2024 Second Quarter Financial Results Conference Call

IDEXX Laboratories Announces Second Quarter Results

IDEXX Laboratories to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

IDEXX Laboratories to Release 2024 Third Quarter Financial Results

IDEXX Laboratories Announces Third Quarter Results

IDEXX Announces CFO Transition

IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization

SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX

Comments

IDEXX Laboratories

Actualités

Dernières nouvelles pour IDEXX Laboratories (NASDAQ:IDXX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL